Child Clinical Trial
Official title:
Pharmacokinetic-guided Dosing of Emicizumab in Congenital Haemophilia A Patients - The DosEmi Study
The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.
Haemophilia A is an X-linked hereditary bleeding disorder resulting from a deficiency or dysfunction of endogenous coagulation factor VIII (FVIII). Persons with haemophilia A (PwHA) suffer from spontaneous or provoked bleeding, predominantly into major joints, which eventually lead to painful and chronic disabling arthropathy. The primary goal in clinical management of haemophilia A is prevention of bleeding by self-administration of FVIII concentrates via intravenous injections. Prophylaxis with FVIII concentrates has effectively reduced treated bleeds from an annual average of 20-30 to 1-4. However, in approximately 30% of PwHA anti-FVIII antibodies (known as inhibitors) develop that interfere with FVIII replacement therapy. PwHA who develop inhibitors require alternative suboptimal therapy with (costly) bypassing agents (BPA). The first approved non-factor therapy is the bispecific, FVIII-mimicking antibody, emicizumab (Hemlibra®), which came available in the Netherlands in July 2018. Emicizumab is a humanized, bispecific antibody connecting factor IX and factor X enabling the activation of FX and subsequent thrombin generation. Emicizumab has shown to be highly effective prophylaxis in PwHA by achieving a complete eradication of treated bleeds in around 80% of PwHA (n = 374) during the second 24-week interval of treatment. Furter advantages of emicizumab are the subcutaneous administration and less frequent dosing intervals every 1, 2 or 4 weeks due to a long half-life (t ½: 28 days). Despite many PwHA are candidate for prophylaxis with emicizumab, cost limit widespread access. Currently, emicizumab is approved by F. Hoffmann-La Roche® with a loading dose of 3 mg/kg/week for four weeks and a maintenance dose of 1.5 mg/kg/week, 3 mg/kg/2 weeks or 6 mg/kg/4 weeks. These dose regimens were based on a pharmacometric approach instead of a dose finding study, and targeted a trough concentration (Ctrough) of 45 µg/ml by using pharmacokinetic (PK)simulations. Meanwhile long-term bleed data from the phase III and IV studies by the pharmaceutical company were included in pharmacokinetic (PK) and pharmacodynamic (PD) modelling studies, and the effective Ctrough was suggested at 30 µg/ml. Although this Ctrough of 30 µg/ml is substantially lower than the previous Ctrough (45 µg/ml), the dose regimens were not adjusted. Conventional dosing leads to mean concentrations of 55 µg/ml with two thirds of the observations between 40 and 70 µg/ml (i.e., SD of ±15 µg/ml). Emicizumab has been approved based on fixed body-weight-based dosing and therefore the concentration target might have been kept higher to avoid lower effectivity due to inter-patient variability. However, reduced dosing of emicizumab, either by extending the dosing interval or lowering the dose, without sacrificing its efficacy has been reported in small case series. Therefore, the investigators hypothesized that lower dosing of emicizumab targeted at Ctrough 30 μg/mL, is equally as effective and less costly in preventing bleeds as conventional dosing of emicizumab, and designed the DosEmi study to investigate the hypothesis in a large prospective cohort of adult and paediatric PwHA. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04011852 -
The Role of Chest Electrical Impedance Tomography in the Pediatric Ventilator Weaning
|
||
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Recruiting |
NCT05016271 -
Health Benefits of Air Purifiers in Primary School Students
|
N/A | |
Completed |
NCT02551978 -
Kids Obesity Prevention Program - Study (KOP)
|
N/A | |
Completed |
NCT02240368 -
Performance Evaluation of the Depth of Anesthesia Monitors in Pediatric Surgery
|
||
Completed |
NCT03946137 -
Chest Therapy and Postural Education in Children With Cerebral Palsy
|
N/A | |
Completed |
NCT01918020 -
Impact Study of Minnesota SNAP-Ed Health and Nutrition Education Programs
|
N/A | |
Completed |
NCT01267097 -
The PAC Study: Parents as Agents of Change in Pediatric Weight Management
|
N/A | |
Recruiting |
NCT04022460 -
Using Personal Mobile Technology to Identify Obstructive Sleep Apnea in Children With Down Syndrome (UPLOAD)
|
||
Completed |
NCT05538039 -
Reducing Anxiety of Children and Their Parents in the Pre-elective Surgery Process
|
N/A | |
Completed |
NCT03156465 -
Iowa Cochlear Implant Clinical Research Center Hybrid L24 and Standard Cochlear Implants in Profoundly Deaf Infants
|
N/A | |
Not yet recruiting |
NCT05914324 -
Outpatient Pediatric Pulse Oximeters in Africa
|
N/A | |
Not yet recruiting |
NCT04827108 -
Psychometric Properties of the Chinese Version of PeNAT
|
||
Recruiting |
NCT04888195 -
Symptom Clusters in Hong Kong Chinese Children With Blood Cancer
|
||
Not yet recruiting |
NCT04853303 -
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
|
N/A | |
Completed |
NCT05374902 -
Efficacy of Animation, Buzzy, and Multiple Interventions on Pain in Children
|
N/A | |
Completed |
NCT04665453 -
Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children
|
N/A | |
Completed |
NCT04082247 -
Healthy Children 2021 Study in Childcare Centers
|
N/A | |
Completed |
NCT02858531 -
Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
|
||
Terminated |
NCT04009031 -
Video Game for Home-based Rehabilitation for Children With Hemiplegia
|
N/A |